161 related articles for article (PubMed ID: 20184570)
1. Invasive cervical cancer audit: why cancers developed in a high-risk population with an organised screening programme.
Herbert A; Anshu ; Culora G; Dunsmore H; Gupta SS; Holdsworth G; Kubba AA; McLean E; Sim J; Raju KS
BJOG; 2010 May; 117(6):736-45. PubMed ID: 20184570
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Cervical screening: why young women should be encouraged to be screened.
Herbert A; Holdsworth G; Kubba AA
J Fam Plann Reprod Health Care; 2008 Jan; 34(1):21-5. PubMed ID: 18201402
[TBL] [Abstract][Full Text] [Related]
4. Invasive cervical cancer audit: a relative increase in interval cancers while coverage increased and incidence declined.
Herbert A; Anshu ; Gregory M; Gupta SS; Singh N
BJOG; 2009 May; 116(6):845-53. PubMed ID: 19432575
[TBL] [Abstract][Full Text] [Related]
5. Review of cytology and histopathology as part of the NHS Cervical Screening Programme audit of invasive cervical cancers.
Castanon A; Ferryman S; Patnick J; Sasieni P
Cytopathology; 2012 Feb; 23(1):13-22. PubMed ID: 22243289
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
[TBL] [Abstract][Full Text] [Related]
7. Risk of significant gynaecological pathology in women with glandular neoplasia on cervical cytology.
Talaat A; Brinkmann D; Dhundee J; Hana Y; Bevan J; Irvine R; Bailey S; Woolas R
Cytopathology; 2012 Dec; 23(6):371-7. PubMed ID: 21749501
[TBL] [Abstract][Full Text] [Related]
8. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
9. The use of screening episodes linked to CIN3 and invasive cancer registrations to study outcomes from the NHS Cervical Screening Programme.
Blanks RG; Moss SM; Coleman DA; Addou S; Swerdlow AJ
Cytopathology; 2009 Jun; 20(3):154-60. PubMed ID: 19207309
[TBL] [Abstract][Full Text] [Related]
10. Cervical intraepithelial neoplasia grade III (CIN III) and invasive cervical carcinoma: the yawning gap revisited and the treatment of risk.
Herbert A; Smith JA
Cytopathology; 1999 Jun; 10(3):161-70. PubMed ID: 10390064
[TBL] [Abstract][Full Text] [Related]
11. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
12. Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening.
Herbert A; Anshu ; Gregory M; Gupta SS; Singh N
BJOG; 2009 May; 116(6):854-9. PubMed ID: 19371308
[TBL] [Abstract][Full Text] [Related]
13. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
14. Risks of cervical intraepithelial neoplasia grade 3 or invasive cancers in ASCUS women with different management: a population-based cohort study.
Tai YJ; Chen YY; Hsu HC; Chiang CJ; You SL; Chen CA; Cheng WF;
J Gynecol Oncol; 2018 Jul; 29(4):e55. PubMed ID: 29770625
[TBL] [Abstract][Full Text] [Related]
15. Histologic findings from the cervix among older women with abnormal cervical cytology.
Massad LS; Behbakht K; Collins YC; Cejtin HE
Gynecol Oncol; 2003 Mar; 88(3):340-4. PubMed ID: 12648584
[TBL] [Abstract][Full Text] [Related]
16. Risk of high-grade cervical intraepithelial neoplasia among young women with abnormal screening cytology.
Massad SL; Markwell S; Cejtin HE; Collins Y
J Low Genit Tract Dis; 2005 Oct; 9(4):225-9. PubMed ID: 16205193
[TBL] [Abstract][Full Text] [Related]
17. [Cervical cancer screening in Italy: quality of colposcopy and treatment. 2010 activity].
Volante R; Giubilato P; Ronco G
Epidemiol Prev; 2012; 36(6 Suppl 1):78-86. PubMed ID: 23293272
[TBL] [Abstract][Full Text] [Related]
18. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
